2. Academic Validation
  3. Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review

Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review

  • Eur J Med Chem. 2021 Dec 15:226:113867. doi: 10.1016/j.ejmech.2021.113867.
Amanda Garrido 1,  Gonzalo Vera 2,  Pierre-Olivier Delaye 3,  Cécile Enguehard-Gueiffier 3
Affiliations

Affiliations

  • 1 Université de Tours, EA 7502 SIMBA Synthèse et Isolement de Molécules Bioactives, 31 Avenue Monge, Tours, France. Electronic address: [email protected].
  • 2 Normandie Univ, UNICAEN, Centre D'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.
  • 3 Université de Tours, EA 7502 SIMBA Synthèse et Isolement de Molécules Bioactives, 31 Avenue Monge, Tours, France.
PMID: 34607244 DOI: 10.1016/j.ejmech.2021.113867
Abstract

Imidazo[1,2-b]pyridazine scaffold represents an important class of heterocyclic nucleus which provides various bioactives molecules. Among them, the successful kinase inhibitor ponatinib led to a resurgence of interest in exploring new imidazo[1,2-b]pyridazine-containing derivatives for their putative therapeutic applications in medicine. This present review intends to provide a state-of-the-art of this framework in medicinal chemistry from 1966 to nowadays, unveiling different aspects of its structure-activity relationships (SAR). This extensive literature surveil may guide medicinal chemists for the quest of novel imidazo[1,2-b]pyridazine compounds with enhanced pharmacokinetics profile and efficiency.

Keywords

Anti-inflammatory; Antibacterial; Anticancer; Antiparasitic; Antiviral; Biological activities; Imidazo[1,2-b]pyridazine; Metabolic disorders; Radiotracers; Sleeping disorders; Structure-activity relationship; Thymic enhancers.

Figures